RxDoctor Payments DataLook up a doctor →

Julie Harper, MD

Dermatology · Birmingham, ALNPI 1841227394

Payments from drug & device makers

$920,398in general payments, 2019–2025

Across 1,413 payments — averaging $651.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Galderma Laboratories, L.p.$435K
  • Sun Pharmaceutical Industries Inc.$121K
  • Ortho Dermatologics, A Division Of Bausch Health US, LLC$112K
  • VYNE Pharmaceuticals Inc.$109K
  • Almirall LLC$27K
  • Aclaris Therapeutics, Inc.$26K
  • plus $91K from 32 others
$20,037in research payments, 2019–2025

Across 5 payments — averaging $4007.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Almirall LLC$20K

What the payments were for

  • Consulting fees$236,90426%
  • Speaking & faculty fees$586,34064%
  • Travel & lodging$52,9586%
  • Food & beverage$43,4735%
  • Education$7230%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$920,398 in reported general payments places this provider in the 95th percentile of 168 dermatology providers in Alabama.

See all dermatology providers in Alabama

Medicare billing

Part B allowed, 2024
$121,577
Medicare patients
386
Services billed
1,887

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast13$61,946
Clobetasol Propionate111$5,719
Fluorouracil57$4,477
Desonide51$2,872
Acitretin12$1,993
Doxycycline Hyclate84$1,436
Metronidazole12$1,023
Econazole Nitrate32$908
Triamcinolone Acetonide57$872
Imiquimod26$804
Minoxidil68$696
MethotrexateMethotrexate Sodium14$397
Ketoconazole18$334
Fluconazole41$282
ValacyclovirValacyclovir Hcl16$215

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$103$61,94613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 168 dermatology providers in Alabama.

Other dermatology in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →